A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Levey AI, Qiu D, Zhao L, Hu WT, et al. Brain 2022;145:1924-1938.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Levey AI, Qiu D, Zhao L, Hu WT, et al. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Brain 2022;145:1924-1938.
PMID: 34919634